Literature DB >> 20549475

Faithfull modeling of PTEN loss driven diseases in the mouse.

Caterina Nardella1, Arkaitz Carracedo, Leonardo Salmena, Pier Paolo Pandolfi.   

Abstract

A decade of work has indisputably defined PTEN as a pivotal player in human health and disease. Above all, PTEN has been identified as one of the most commonly lost or mutated tumor suppressor genes in human cancers. For this reason, the generation of a multitude of mouse models has been an invaluable strategy to dissect the function and consequences-of-loss of this essential, evolutionary conserved lipid phosphatase in tumor initiation and progression.In this chapter, we will summarize the mouse models that have allowed us to faithfully recapitulate features of human cancers and to highlight the network of connections between the PTEN signaling cascade and other oncogenic or tumor suppressive pathways.Notably, PTEN represents one of the most extensively modeled genes involved in human cancer and exemplifies the strength of genetic mouse modeling as an approach to gain information aimed to improve our understanding of and ability to alleviate human disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20549475     DOI: 10.1007/82_2010_62

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  27 in total

1.  Phosphatase and tensin homologue (PTEN) regulates synaptic plasticity independently of its effect on neuronal morphology and migration.

Authors:  Margaret Sperow; Raymond B Berry; Ildar T Bayazitov; Guo Zhu; Suzanne J Baker; Stanislav S Zakharenko
Journal:  J Physiol       Date:  2011-12-06       Impact factor: 5.182

Review 2.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

3.  Nuclear PTEN deficiency causes microcephaly with decreased neuronal soma size and increased seizure susceptibility.

Authors:  Atsushi Igarashi; Kie Itoh; Tatsuya Yamada; Yoshihiro Adachi; Takashi Kato; Daisuke Murata; Hiromi Sesaki; Miho Iijima
Journal:  J Biol Chem       Date:  2018-05-07       Impact factor: 5.157

4.  Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model.

Authors:  Nicolas Floc'h; Carolyn Waugh Kinkade; Takashi Kobayashi; Alvaro Aytes; Celine Lefebvre; Antonina Mitrofanova; Robert D Cardiff; Andrea Califano; Michael M Shen; Cory Abate-Shen
Journal:  Cancer Res       Date:  2012-07-19       Impact factor: 12.701

5.  Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis.

Authors:  Caterina Nardella; Andrea Lunardi; Giuseppe Fedele; John G Clohessy; Andrea Alimonti; Sara C Kozma; George Thomas; Massimo Loda; Pier Paolo Pandolfi
Journal:  Cancer Res       Date:  2011-03-28       Impact factor: 12.701

6.  Deregulation of the endogenous C/EBPβ LIP isoform predisposes to tumorigenesis.

Authors:  Valérie Bégay; Jeske J Smink; Christoph Loddenkemper; Karin Zimmermann; Cornelia Rudolph; Marina Scheller; Doris Steinemann; Ulf Leser; Brigitte Schlegelberger; Harald Stein; Achim Leutz
Journal:  J Mol Med (Berl)       Date:  2014-11-18       Impact factor: 4.599

7.  In Vivo Assessment of Metastatic Cell Potential in Prostate Cancer.

Authors:  Marc Nunez-Olle; Marc Guiu; Roger R Gomis
Journal:  Methods Mol Biol       Date:  2021

Review 8.  PTEN level in tumor suppression: how much is too little?

Authors:  Arkaitz Carracedo; Andrea Alimonti; Pier Paolo Pandolfi
Journal:  Cancer Res       Date:  2011-01-25       Impact factor: 12.701

9.  Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.

Authors:  Eleonora Sementino; Craig W Menges; Yuwaraj Kadariya; Suraj Peri; Jinfei Xu; Zemin Liu; Richard G Wilkes; Kathy Q Cai; Frank J Rauscher; Andres J Klein-Szanto; Joseph R Testa
Journal:  J Cell Physiol       Date:  2018-06-15       Impact factor: 6.384

10.  B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer.

Authors:  Jingqiang Wang; Takashi Kobayashi; Nicolas Floc'h; Carolyn Waugh Kinkade; Alvaro Aytes; David Dankort; Celine Lefebvre; Antonina Mitrofanova; Robert D Cardiff; Martin McMahon; Andrea Califano; Michael M Shen; Cory Abate-Shen
Journal:  Cancer Res       Date:  2012-07-25       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.